Derived from the bronchioalveolar cancer of a human patient
by A.F. Gazdar in 1981, the NCI-H358 cell line has served as a stable testing
environment for lung cancer drug evaluations during preclinical trials. As an in vitro model for the testing of drugs,
the NCI-H358 cell line can be transfected with optimal reagents
to ensure the realistic nature of results pertaining to genetic mutations and
resulting effects on cell proliferation. With a population doubling time of
roughly 38 hours, the cell line is well-suited for preclinical research and
drug testing that may lead to clinical trials.
The NCI-H358 cell line was first established in 1981 from removed bronchiole tissue of a patient suffering from bronchioalveolar carcinoma (lung cancer). The tissue was removed from the patient prior to any administered chemotherapy treatments. The NCI-H358 cell line has a doubling time of about 38 hours, it has detectable Clara cells and is an exceptional transfection host. This cell line is also a great candidate for in vitro research studies, such as those at Altogen Biosystems . T he in vitro research models are helpful to solving lung cancer and useful as transfection hosts. Transfection Reagent for NCI-H358 Cells (Bronchioalveolar Cells, CRL-5807)
Comments
Post a Comment